Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Chronic Heart Failure

Free Subscription Articles published in Circulation Retrieve available abstracts of 165 articles: HTML format

Single Articles

June 2025
1. GUO X, Huang C, Zhang L, Hu G, et al
   Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF.
   Circulation. 2025;151:1651-1666.
   PubMed     Abstract available
   
   
   
2. PANDEY A, Thomas T, Ji Y, Kroger B, et al
   TET2-Mutant Clonal Hematopoiesis Promotes Heart Failure With Preserved Ejection Fraction.
   Circulation. 2025;151:1622-1625.
   PubMed    
   
   
   
3. FONSEKA O, Raja R, Ross C, Gare SR, et al
   XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity.
   Circulation. 2025;151:1583-1605.
   PubMed     Abstract available
   
   
   May 2025
4. ZHENG Y, Cao Y, Wang W, Tong Y, et al
   Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart Failure.
   Circulation. 2025 May 13. doi: 10.1161/CIRCULATIONAHA.125.074353.
   PubMed     Abstract available
   
   
   
5. METRA M, Tomasoni D, Adamo M, Anker SD, et al
   Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions.
   Circulation. 2025;151:1342-1363.
   PubMed     Abstract available
   
   
   
6. MICHEL LYM, Esfahani H, De Mulder D, Verdoy R, et al
   An NRF2/beta3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress.
   Circulation. 2025;151:1312-1328.
   PubMed     Abstract available
   
   
   April 2025
7. NAKAMORI S, Omori T, Fujimoto N, Ishida M, et al
   Interplay Between Epicardial Adipose Tissue and Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction.
   Circulation. 2025;151:1294-1296.
   PubMed    
   
   
   
8. KHAN SS, Breathett K, Braun LT, Chow SL, et al
   Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association.
   Circulation. 2025 Apr 16. doi: 10.1161/CIR.0000000000001307.
   PubMed     Abstract available
   
   
   
9. BUTLER J, Usman MS, Gandotra C, Salman A, et al
   Patient-Reported Outcomes as End Points in Heart Failure Trials.
   Circulation. 2025;151:1111-1125.
   PubMed     Abstract available
   
   
   
10. OMLAND T, Mills NL
    Natriuretic Peptides for the Diagnosis of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025;151:990-992.
    PubMed    
    
    
    
11. GLARGAARD S, Hartvig Thomsen J, Tuxen C, Lindholm MG, et al
    A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
    Circulation. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.073521.
    PubMed     Abstract available
    
    
    March 2025
12. EBERLY L, Tennison A, Morgan L, Smith M, et al
    Centering Dine (Navajo) Voices: Barriers, Facilitators, and Perceptions of Cardiac Care among Patients with Heart Failure in Rural Navajo Nation.
    Circulation. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.124.073166.
    PubMed     Abstract available
    
    
    
13. KAR S, Makkar RR, Whisenant BK, Hamid N, et al
    Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial.
    Circulation. 2025 Mar 30. doi: 10.1161/CIRCULATIONAHA.125.074536.
    PubMed     Abstract available
    
    
    
14. CHEN L, Hu Y, Saguner AM, Bauce B, et al
    Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy.
    Circulation. 2025 Mar 24. doi: 10.1161/CIRCULATIONAHA.124.072226.
    PubMed     Abstract available
    
    
    
15. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2025;151:e763.
    PubMed    
    
    
    
16. BASILE C, Lindberg F, Benson L, Guidetti F, et al
    Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction.
    Circulation. 2025 Mar 17. doi: 10.1161/CIRCULATIONAHA.124.072855.
    PubMed     Abstract available
    
    
    
17. FILIPP M, Ge ZD, DeBerge M, Lantz C, et al
    Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction.
    Circulation. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.070248.
    PubMed     Abstract available
    
    
    
18. DAI H, Lu X, Zhou X
    Letter by Dai et al Regarding Article, "Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction".
    Circulation. 2025;151:e686.
    PubMed    
    
    
    
19. YANCY CW
    Heart Failure: A Century View, From Failure to Function.
    Circulation. 2025;151:585-588.
    PubMed    
    
    
    February 2025
20. LIU X, Wang Q, Li X, Yang Y, et al
    Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA.
    Circulation. 2025 Feb 20. doi: 10.1161/CIRCULATIONAHA.124.070840.
    PubMed     Abstract available
    
    
    
21. BRAUMANN S, Macherey-Meyer S, Polzin A, Costard-Jackle A, et al
    MYSTERY-HF - Myeloperoxidase Inhibition in Patients With Heart Failure and Reduced Ejection Fraction - a Phase II Randomized Controlled Trial.
    Circulation. 2025 Feb 12. doi: 10.1161/CIRCULATIONAHA.125.074085.
    PubMed    
    
    
    
22. SHEN L, Jhund PS, McMurray JJV
    Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF".
    Circulation. 2025;151:e38.
    PubMed    
    
    
    
23. TUNCEZ A, Gurses KM
    Letter by Tuncez and Gurses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF".
    Circulation. 2025;151:e37.
    PubMed    
    
    
    January 2025
24. KUEHN BM
    Kidney Decline Predicts Worse Heart Failure Outcomes.
    Circulation. 2025;151:348-350.
    PubMed    
    
    
    
25. REDDY YNV, Tada A, Obokata M, Carter RE, et al
    Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting.
    Circulation. 2025 Jan 22. doi: 10.1161/CIRCULATIONAHA.124.072156.
    PubMed     Abstract available
    
    
    
26. PARK SJ, Kang DH
    Response by Park and Kang to Letter Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e28.
    PubMed    
    
    
    
27. MORDI IR, McCrimmon RJ, Lang CC
    SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
    Circulation. 2025;151:199-201.
    PubMed    
    
    
    
28. WANG J, Peng Y
    Letter by Wang and Peng Regarding Article, "Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial".
    Circulation. 2025;151:e27.
    PubMed    
    
    
    
29. DERKS W, Rode J, Collin S, Rost F, et al
    A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease.
    Circulation. 2025;151:245-256.
    PubMed     Abstract available
    
    
    December 2024
30. YAMADA Y, Sadahiro T, Nakano K, Honda S, et al
    Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Dec 14. doi: 10.1161/CIRCULATIONAHA.123.067504.
    PubMed     Abstract available
    
    
    
31. DOI SN, Butt JH, Thune JJ, Nielsen JC, et al
    Left Ventricular Ejection Fraction and Implantable Cardioverter-Defibrillator in Non-ischemic Heart Failure with Reduced Ejection Fraction: Insights from DANISH.
    Circulation. 2024 Dec 10. doi: 10.1161/CIRCULATIONAHA.124.071777.
    PubMed    
    
    
    
32. ALVAREZ-GARCIA J
    Cognitive Dysfunction in Heart Failure With Preserved Ejection Fraction: Uncovering the Consequences of an Overlooked Comorbidity.
    Circulation. 2024;150:1928-1930.
    PubMed    
    
    
    
33. YANG X, Zhang Z
    Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial".
    Circulation. 2024;150:e468.
    PubMed    
    
    
    
34. SANDHU AT, Spertus JA, Heidenreich PA
    Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial".
    Circulation. 2024;150:e469-e470.
    PubMed    
    
    
    November 2024
35. KEHR D, Ritterhoff J, Glaser M, Jarosch L, et al
    S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models.
    Circulation. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.066961.
    PubMed     Abstract available
    
    
    
36. JI Y, Zhang MJ, Wang W, Norby FL, et al
    Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS.
    Circulation. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.124.070278.
    PubMed     Abstract available
    
    
    
37. ZILE MR, Borlaug BA, Kramer CM, Baum SJ, et al
    Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity.
    Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072679.
    PubMed     Abstract available
    
    
    
38. VOORRIPS SN, Westenbrink BD
    Ketone Treatment in Heart Failure With Preserved Ejection Fraction: Recharging the Heart or Reducing Filling Pressures?
    Circulation. 2024;150:1584-1587.
    PubMed    
    
    
    October 2024
39. SHEN L, Dewan P, Ferreira JP, Cunningham JW, et al
    Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    Circulation. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070553.
    PubMed     Abstract available
    
    
    
40. SOHNS C, Sommer P
    Patients With Advanced Heart Failure and Atrial Fibrillation Deserve an Attempt at Catheter Ablation as First-Line Therapy.
    Circulation. 2024;150:1220-1222.
    PubMed    
    
    
    
41. BEDIOUNE I, Gandon-Renard M, Dessillons M, Barthou A, et al
    Essential Role of the RIalpha Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development.
    Circulation. 2024 Oct 2. doi: 10.1161/CIRCULATIONAHA.124.068858.
    PubMed     Abstract available
    
    
    
42. JIA K, Cheng H, Ma W, Zhuang L, et al
    RNA Helicase DDX5 Maintains Cardiac Function by Regulating CamkIIdelta Alternative Splicing.
    Circulation. 2024;150:1121-1139.
    PubMed     Abstract available
    
    
    
43. KNEUER JM, Grajek IA, Winkler M, Erbe S, et al
    Novel Long Noncoding RNA HEAT4 Affects Monocyte Subtypes, Reducing Inflammation and Promoting Vascular Healing.
    Circulation. 2024;150:1101-1120.
    PubMed     Abstract available
    
    
    September 2024
44. DOCHERTY KF, Henderson AD, Jhund PS, Claggett BL, et al
    Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial.
    Circulation. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011.
    PubMed     Abstract available
    
    
    
45. VADUGANATHAN M, Claggett BL, Kulac IJ, Miao ZM, et al
    Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure.
    Circulation. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055.
    PubMed     Abstract available
    
    
    
46. SHADDY R, Burch M, Kantor PF, Solar-Yohay S, et al
    Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
    Circulation. 2024 Sep 25. doi: 10.1161/CIRCULATIONAHA.123.066605.
    PubMed     Abstract available
    
    
    
47. STONE GW, Lindenfeld J, Rodes-Cabau J, Anker SD, et al
    Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
    Circulation. 2024 Sep 23. doi: 10.1161/CIRCULATIONAHA.124.070870.
    PubMed     Abstract available
    
    
    
48. WANG J, Chen B, Shi Q, Ciampa G, et al
    Preventing Site-Specific Calpain Proteolysis of Junctophilin-2 Protects Against Stress-Induced Excitation-Contraction Uncoupling and Heart Failure Development.
    Circulation. 2024 Sep 18. doi: 10.1161/CIRCULATIONAHA.124.069329.
    PubMed     Abstract available
    
    
    
49. 
    Correction to: Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024;150:e268.
    PubMed    
    
    
    
50. TANG WHW, Bakitas MA, Cheng XS, Fang JC, et al
    Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Sep 10. doi: 10.1161/CIR.0000000000001273.
    PubMed     Abstract available
    
    
    
51. KOSIBOROD MN, Petrie MC, Borlaug BA
    Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial".
    Circulation. 2024;150:e226-e227.
    PubMed    
    
    
    
52. WEIR RAP
    Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
    Circulation. 2024;150:e224-e225.
    PubMed    
    
    
    
53. BUTT JH, McMurray JJ, Claggett BL, Jhund PS, et al
    Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials.
    Circulation. 2024 Sep 1. doi: 10.1161/CIRCULATIONAHA.124.071110.
    PubMed     Abstract available
    
    
    August 2024
54. SOHNS C, Moersdorf M, Marrouche NF, Bergau L, et al
    Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation: Two-year Follow-up of the CASTLE-HTx Trial.
    Circulation. 2024 Aug 30. doi: 10.1161/CIRCULATIONAHA.124.071517.
    PubMed    
    
    
    
55. GOPALASINGAM N, Berg-Hansen K, Christensen KH, Ladefoged BT, et al
    Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732.
    PubMed     Abstract available
    
    
    
56. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Response by Chatur et al to Letter Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial".
    Circulation. 2024;150:e107-e108.
    PubMed    
    
    
    
57. WANG J
    Letter by Wang Regarding Article, "Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial".
    Circulation. 2024;150:e106.
    PubMed    
    
    
    
58. GREENE SJ, Butler J, Fonarow GC
    Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles.
    Circulation. 2024;150:422-424.
    PubMed    
    
    
    
59. NETUKA I, Tucanova Z, Ivak P, Gregor S, et al
    A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study.
    Circulation. 2024;150:509-511.
    PubMed    
    
    
    
60. TADA A, Burkhoff D, Naser JA, Harada T, et al
    Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial.
    Circulation. 2024 Aug 5. doi: 10.1161/CIRCULATIONAHA.124.068788.
    PubMed     Abstract available
    
    
    July 2024
61. ABOUMSALLEM JP, de Boer RA
    IGFBP7: From Senescence Biomarker to a Vaccine for Heart Failure.
    Circulation. 2024;150:390-392.
    PubMed    
    
    
    
62. YOO SGK, Lam CSP, Sweitzer NK
    "Asian" Heart Failure.
    Circulation. 2024;150:177-179.
    PubMed    
    
    
    
63. WEYRICH M, Cremer S, Gerster M, Sarakpi T, et al
    Loss of Y Chromosome and Cardiovascular Events in Chronic Kidney Disease.
    Circulation. 2024 Jul 15. doi: 10.1161/CIRCULATIONAHA.124.069139.
    PubMed     Abstract available
    
    
    
64. KATOH M, Nomura S, Yamada S, Ito M, et al
    Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
    Circulation. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.064719.
    PubMed     Abstract available
    
    
    
65. 
    Correction to: Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2024;150:e63.
    PubMed    
    
    
    June 2024
66. HOEPER MM, Oerke B, Wissmuller M, Leuchte H, et al
    Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.
    Circulation. 2024 Jun 28. doi: 10.1161/CIRCULATIONAHA.124.069340.
    PubMed     Abstract available
    
    
    
67. NASER JA, Tada A, Harada T, Reddy YNV, et al
    Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024;149:2026-2028.
    PubMed    
    
    
    
68. DEWAN P, Shen L, Pedro Ferreira J, Jhund PS, et al
    Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.
    Circulation. 2024 Jun 6. doi: 10.1161/CIRCULATIONAHA.124.068774.
    PubMed     Abstract available
    
    
    May 2024
69. AMDANI S, Conway J, George K, Martinez HR, et al
    Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2024 May 29. doi: 10.1161/CIR.0000000000001245.
    PubMed     Abstract available
    
    
    
70. JHENG JR, Bai Y, Noda K, Huot JR, et al
    Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 May 28. doi: 10.1161/CIRCULATIONAHA.124.068624.
    PubMed     Abstract available
    
    
    
71. CALLER T, Rotem I, Shaihov-Teper O, Lendengolts D, et al
    Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth.
    Circulation. 2024;149:1729-1748.
    PubMed     Abstract available
    
    
    
72. PACKER M, Anker SD, Butler J, Cleland JGF, et al
    Redefining Iron Deficiency in Patients With Chronic Heart Failure.
    Circulation. 2024 May 11. doi: 10.1161/CIRCULATIONAHA.124.068883.
    PubMed    
    
    
    
73. SARMA S, Dyck JRB
    Unlocking Pathways That Improve Cardiac Function in Chronic Heart Failure: Are Ketones the Key?
    Circulation. 2024;149:1490-1492.
    PubMed    
    
    
    
74. KANG DH, Park SJ, Shin SH, Hwang IC, et al
    Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
    Circulation. 2024 May 1. doi: 10.1161/CIRCULATIONAHA.124.069144.
    PubMed     Abstract available
    
    
    April 2024
75. ZHANG F, Zhang L, Hu G, Chen X, et al
    Rectifying METTL4-Mediated N(6)-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure.
    Circulation. 2024 Apr 30. doi: 10.1161/CIRCULATIONAHA.123.068358.
    PubMed     Abstract available
    
    
    
76. LEMESLE G, Lamblin N, Schurtz G, Labreuche J, et al
    Comparison of Incidence and Prognostic Impact of Ischemic Major Bleeding and Heart Failure Events in Patients With Chronic Coronary Syndrome: Insights From the CORONOR Registry.
    Circulation. 2024 Apr 25. doi: 10.1161/CIRCULATIONAHA.123.067938.
    PubMed     Abstract available
    
    
    
77. SWAIN L, Bhave S, Qiao X, Reyelt L, et al
    Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation.
    Circulation. 2024;149:1341-1353.
    PubMed     Abstract available
    
    
    
78. 
    Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
    Circulation. 2024;149:e1130.
    PubMed    
    
    
    
79. LI B, Liu F, Chen X, Chen T, et al
    FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System.
    Circulation. 2024;149:1268-1284.
    PubMed     Abstract available
    
    
    
80. SANDHU AT, Calma J, Skye M, Kalwani NM, et al
    Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624.
    PubMed     Abstract available
    
    
    
81. HERNANDEZ AF, Udell JA, Jones WS, Anker SD, et al
    Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
    Circulation. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217.
    PubMed     Abstract available
    
    
    
82. BREATHETT K, Lewsey S, Brownell NK, Enright K, et al
    Implementation Science to Achieve Equity in Heart Failure Care: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Apr 3. doi: 10.1161/CIR.0000000000001231.
    PubMed     Abstract available
    
    
    
83. 
    Correction to: INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2024;149:e1066.
    PubMed    
    
    
    
84. GOKULNATH P, Spanos M, Lehmann HI, Sheng Q, et al
    Distinct Plasma Extracellular Vesicle Transcriptomes in Acute Decompensated Heart Failure Subtypes: A Liquid Biopsy Approach.
    Circulation. 2024;149:1147-1149.
    PubMed    
    
    
    
85. KAPELIOS CJ, Lund LH
    Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure.
    Circulation. 2024;149:1062-1064.
    PubMed    
    
    
    March 2024
86. BERG-HANSEN K, Gopalasingam N, Christensen KH, Ladefoged B, et al
    Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind Trial.
    Circulation. 2024 Mar 27. doi: 10.1161/CIRCULATIONAHA.123.067971.
    PubMed     Abstract available
    
    
    
87. JESSUP M
    A Century of Heart Failure With Reduced Ejection Fraction: Mostly Drought, Followed by Rapid Progress.
    Circulation. 2024;149:899-901.
    PubMed    
    
    
    
88. CLELAND JGF
    Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure.
    Circulation. 2024;149:839-842.
    PubMed    
    
    
    
89. VELIKANOVA D, Poyhonen P, Lehtonen J, Simonen P, et al
    End-Stage Heart Failure in Cardiac Sarcoidosis.
    Circulation. 2024;149:885-887.
    PubMed    
    
    
    February 2024
90. HOEDEMAKERS S, Pugliese NR, Stassen J, Vanoppen A, et al
    mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis.
    Circulation. 2024 Feb 27. doi: 10.1161/CIRCULATIONAHA.123.067130.
    PubMed     Abstract available
    
    
    
91. CRESCI S, Bach RG, Saberi S, Owens AT, et al
    Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Circulation. 2024;149:498-509.
    PubMed     Abstract available
    
    
    
92. GREEN JB, Everett BM, Ghosh A, Younes N, et al
    Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
    Circulation. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604.
    PubMed     Abstract available
    
    
    
93. JIANG Y, Gu J, Niu X, Hu J, et al
    Phosphorylation-Regulated Dynamic Phase Separation of HIP-55 Protects Against Heart Failure.
    Circulation. 2024 Feb 8. doi: 10.1161/CIRCULATIONAHA.123.067519.
    PubMed     Abstract available
    
    
    
94. SANCHEZ RH, Hamdan H, Torrealba J, Grodin JL, et al
    Giants Hiding in Small Places: A Case of New Onset Heart Failure, Atrioventricular Block, and Ventricular Arrhythmias.
    Circulation. 2024;149:475-480.
    PubMed    
    
    
    January 2024
95. HERWEG B, Sharma PS, Cano O, Ponnusamy SS, et al
    Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study.
    Circulation. 2024;149:379-390.
    PubMed     Abstract available
    
    
    
96. SUMARSONO A, Xie L, Keshvani N, Zhang C, et al
    Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
    Circulation. 2024 Jan 23. doi: 10.1161/CIRCULATIONAHA.123.067489.
    PubMed     Abstract available
    
    
    
97. BROMAN MT, Nadadur RD, Perez-Cervantes C, Burnicka-Turek O, et al
    A Genomic Link From Heart Failure to Atrial Fibrillation Risk: FOG2 Modulates a TBX5/GATA4-Dependent Atrial Gene Regulatory Network.
    Circulation. 2024 Jan 8. doi: 10.1161/CIRCULATIONAHA.123.066804.
    PubMed     Abstract available
    
    
    December 2023
98. REN Z, Zhao W, Li D, Yu P, et al
    INO80-Dependent Remodeling of Transcriptional Regulatory Network Underlies the Progression of Heart Failure.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.065440.
    PubMed     Abstract available
    
    
    
99. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    PubMed     Abstract available
    
    
    
100. THOMPSON PD
     Steps May Count for More Than Just Cardiac Risk.
     Circulation. 2023;148:2017-2018.
     PubMed    
     
     
     
101. GOSS KN
     Preterm Birth: An Overlooked Risk Factor for Heart Failure in the Young Adult.
     Circulation. 2023;148:2005-2007.
     PubMed    
     
     
     
102. GOLDENBERG JR, Hays AG, Gabr RE, Sch?r M, et al
     Energetic Basis of Recovered Ejection Fraction in Human Heart Failure.
     Circulation. 2023;148:1976-1978.
     PubMed    
     
     
     
103. VAN DUIJVENBODEN S, Ramirez J, Orini M, Aung N, et al
     Prognostic Significance of Different Ventricular Ectopic Burdens During Submaximal Exercise in Asymptomatic UK Biobank Subjects.
     Circulation. 2023;148:1932-1944.
     PubMed     Abstract available
     
     
     
104. MCMURRAY JJV, Docherty KF, de Boer RA, Hammarstedt A, et al
     Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
     Circulation. 2023 Dec 7. doi: 10.1161/CIRCULATIONAHA.123.065061.
     PubMed     Abstract available
     
     
     November 2023
105. GREENE SJ, Butler J
     Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics.
     Circulation. 2023;148:1746-1749.
     PubMed    
     
     
     
106. WALKER MA, Chen H, Yadav A, Ritterhoff J, et al
     Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation.
     Circulation. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039.
     PubMed     Abstract available
     
     
     
107. XU W, Billon C, Li H, Wilderman A, et al
     Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
     Circulation. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542.
     PubMed     Abstract available
     
     
     
108. WHELLAN DJ
     Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume.
     Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588.
     PubMed    
     
     
     
109. VETROVSKY T, Siranec M, Frybova T, Gant I, et al
     Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
     Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395.
     PubMed     Abstract available
     
     
     
110. KOSIBOROD MN, Verma S, Borlaug BA, Butler J, et al
     Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
     Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067505.
     PubMed     Abstract available
     
     
     
111. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
     Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
     Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
     PubMed     Abstract available
     
     
     
112. KHAN SS, Coresh J, Pencina MJ, Ndumele CE, et al
     Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.
     Circulation. 2023 Nov 10. doi: 10.1161/CIR.0000000000001191.
     PubMed     Abstract available
     
     
     
113. KHAN SS, Matsushita K, Sang Y, Ballew SH, et al
     Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations.
     Circulation. 2023 Nov 10. doi: 10.1161/CIRCULATIONAHA.123.067626.
     PubMed     Abstract available
     
     
     
114. BAWASKAR P, Thomas N, Ismail KF, Guo Y, et al
     Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease.
     Circulation. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067032.
     PubMed     Abstract available
     
     
     October 2023
115. ZAMANI SK, Sarma S, MacNamara JP, Hynan LS, et al
     Excess Pericardial Fat Is Related to Adverse Cardio-Mechanical Interaction in Heart Failure With Preserved Ejection Fraction.
     Circulation. 2023;148:1410-1412.
     PubMed    
     
     
     
116. WAKEHAM DJ, Ivey E, Saland S, Lewis J, et al
     Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
     Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.066170.
     PubMed     Abstract available
     
     
     
117. OSTROMINSKI JW, Vaduganathan M, Selvaraj S, Claggett BL, et al
     Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
     Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065254.
     PubMed     Abstract available
     
     
     
118. BUTT JH, Yafasova A, Doi SN, Nielsen JC, et al
     Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial.
     Circulation. 2023;148:1179-1181.
     PubMed    
     
     
     September 2023
119. GODFREY S, Kirkpatrick JN, Kramer DB, Sulistio MS, et al
     Expanding the Paradigm for Cardiovascular Palliative Care.
     Circulation. 2023;148:1039-1052.
     PubMed     Abstract available
     
     
     
120. PARKASH R, O'Meara E, Tang ASL
     The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure.
     Circulation. 2023;148:933-935.
     PubMed    
     
     
     
121. LEBEK S, Caravia XM, Chemello F, Tan W, et al
     Elimination of CaMKIIdelta Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice.
     Circulation. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117.
     PubMed     Abstract available
     
     
     
122. COCHRAN J, Yura Y, Thel MC, Doviak H, et al
     Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.
     Circulation. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170.
     PubMed     Abstract available
     
     
     
123. CHEW DS, Li Y, Bigelow R, Cowper PA, et al
     Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
     Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602.
     PubMed     Abstract available
     
     
     
124. ZHU H, Song YC, Hang PZ
     Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
     Circulation. 2023;148:855-856.
     PubMed    
     
     
     
125. ARONSEN JM, Skogestad J, Albert I, Melleby AO, et al
     Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
     Circulation. 2023;148:857-858.
     PubMed    
     
     
     August 2023
126. HEIDENREICH P
     What Is a Normal Left Ventricular Ejection Fraction?
     Circulation. 2023;148:750-752.
     PubMed    
     
     
     
127. CHATUR S, Vaduganathan M, Claggett BL, Cunningham JW, et al
     Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
     Circulation. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506.
     PubMed     Abstract available
     
     
     
128. PACKER M, Butler J, Zeller C, Pocock SJ, et al
     Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
     Circulation. 2023 Aug 24. doi: 10.1161/CIRCULATIONAHA.123.065748.
     PubMed    
     
     
     
129. 
     Correction to: Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
     Circulation. 2023;148:e7.
     PubMed    
     
     
     
130. SARMA S, Levine BD
     Response by Sarma and Levine to Letters Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
     Circulation. 2023;148:620-621.
     PubMed    
     
     
     
131. WUSSLER D, Belkin M, Mueller C
     Letter by Wussler et al Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
     Circulation. 2023;148:619.
     PubMed    
     
     
     
132. RAGONE I, Barallobre-Barreiro J, Takov K, Theofilatos K, et al
     SERCA2a Protein Levels Are Unaltered in Human Heart Failure.
     Circulation. 2023;148:613-616.
     PubMed    
     
     
     
133. DIMOPOULOS S, Nanas S
     Letter by Dimopoulos and Nanas Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
     Circulation. 2023;148:617-618.
     PubMed    
     
     
     
134. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
     Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
     Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
     PubMed     Abstract available
     
     
     July 2023
135. PACKER M, Wilcox CS, Testani JM
     Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
     Circulation. 2023;148:354-372.
     PubMed     Abstract available
     
     
     
136. MENTIAS A, Mujahid MS, Sumarsono A, Nelson RK, et al
     Historical Redlining, Socioeconomic Distress, and Risk of Heart Failure Among Medicare Beneficiaries.
     Circulation. 2023;148:210-219.
     PubMed     Abstract available
     
     
     
137. WATSON WD, Green PG, Lewis AJM, Arvidsson P, et al
     Retained Metabolic Flexibility of the Failing Human Heart.
     Circulation. 2023;148:109-123.
     PubMed     Abstract available
     
     
     
138. GHADIMI K, Cappiello JL, Wright MC, Levy JH, et al
     Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
     Circulation. 2023 Jul 4. doi: 10.1161/CIRCULATIONAHA.122.062464.
     PubMed     Abstract available
     
     
     June 2023
139. KONDO T, Dewan P, Anand IS, Desai AS, et al
     Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
     Circulation. 2023 Jun 27. doi: 10.1161/CIRCULATIONAHA.122.063642.
     PubMed     Abstract available
     
     
     
140. HITSUMOTO T, Tsukamoto O, Matsuoka K, Li J, et al
     Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin.
     Circulation. 2023;147:1902-1918.
     PubMed     Abstract available
     
     
     May 2023
141. TANG Y, Feng M, Su Y, Ma T, et al
     Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
     Circulation. 2023;147:1684-1704.
     PubMed     Abstract available
     
     
     
142. GREENE SJ, Velazquez EJ, Anstrom KJ, Clare RM, et al
     Effect of Torsemide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
     Circulation. 2023 May 22. doi: 10.1161/CIRCULATIONAHA.123.064842.
     PubMed     Abstract available
     
     
     
143. JANI V, Aslam MI, Fenwick AJ, Ma W, et al
     Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension.
     Circulation. 2023 May 17. doi: 10.1161/CIRCULATIONAHA.123.064717.
     PubMed     Abstract available
     
     
     
144. GUPTA K, Spertus JA, Birmingham M, Gosch KL, et al
     Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
     Circulation. 2023 May 16. doi: 10.1161/CIRCULATIONAHA.122.063263.
     PubMed     Abstract available
     
     
     
145. SATTAR N, McMurray J, Boren J, Rawshani A, et al
     Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
     Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
     PubMed     Abstract available
     
     
     April 2023
146. HUNDERTMARK MJ, Adler A, Antoniades C, Coleman R, et al
     Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
     Circulation. 2023 Apr 18. doi: 10.1161/CIRCULATIONAHA.122.062021.
     PubMed     Abstract available
     
     
     
147. BUTLER J, Talha KM, Fonarow GC
     STRONG-HF and Implementing Heart Failure Therapies: Godspeed ... With Care.
     Circulation. 2023;147:1189-1191.
     PubMed    
     
     
     
148. FILIPPATOS G, Ponikowski P, Farmakis D, Anker SD, et al
     Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
     Circulation. 2023 Apr 13. doi: 10.1161/CIRCULATIONAHA.122.060757.
     PubMed     Abstract available
     
     
     
149. ERN YEOH S, Docherty KF, Campbell RT, Jhund PS, et al
     Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
     Circulation. 2023 Apr 11. doi: 10.1161/CIRCULATIONAHA.122.063327.
     PubMed     Abstract available
     
     
     
150. MENTIAS A, Peterson ED, Keshvani N, Kumbhani DJ, et al
     Achieving Equity in Hospital Performance Assessments Using Composite Race-Specific Measures of Risk-Standardized Readmission and Mortality Rates for Heart Failure.
     Circulation. 2023;147:1121-1133.
     PubMed     Abstract available
     
     
     
151. 
     Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
     Circulation. 2023;147:e674.
     PubMed    
     
     
     
152. BUTT JH, Solomon SD, McMurray JJV
     Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
     Circulation. 2023;147:1119-1120.
     PubMed    
     
     
     
153. WONG EKC, Demers C
     Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
     Circulation. 2023;147:1118.
     PubMed    
     
     
     March 2023
154. SACHDEV V, Sharma K, Keteyian SJ, Alcain CF, et al
     Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.
     Circulation. 2023 Mar 21. doi: 10.1161/CIR.0000000000001122.
     PubMed     Abstract available
     
     
     
155. SELVARAJ S, Kosiborod MN, Shah SH
     Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
     Circulation. 2023;147:922-923.
     PubMed    
     
     
     
156. TACHIBANA S, Yu NK, Li R, Fernandez-Costa C, et al
     Perm1 Protects the Heart From Pressure Overload-Induced Dysfunction by Promoting Oxidative Metabolism.
     Circulation. 2023;147:916-919.
     PubMed    
     
     
     
157. MONZO L, Melenovsky V
     Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
     Circulation. 2023;147:920-921.
     PubMed    
     
     
     
158. MENG Z, Zhang Z, Zhao J, Liu C, et al
     Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
     Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
     PubMed     Abstract available
     
     
     
159. KUEHN BM
     Collaborative Care Model Helps Patients With Heart Failure Meet End-of-Life Goals.
     Circulation. 2023;147:841-842.
     PubMed    
     
     
     
160. FRIEDMAN DJ, Al-Khatib SM, Dalgaard F, Fudim M, et al
     Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.
     Circulation. 2023;147:812-823.
     PubMed     Abstract available
     
     
     
161. SKOGESTAD J, Albert I, Hougen K, Lothe GB, et al
     Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.
     Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.121.054168.
     PubMed     Abstract available
     
     
     
162. KONDO T, Jering KS, Borleffs CJW, de Boer RA, et al
     Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
     Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.122.062918.
     PubMed     Abstract available
     
     
     
163. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
     Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
     Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
     PubMed     Abstract available
     
     
     February 2023
164. LEYVA F, Israel CW, Singh J
     Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
     Circulation. 2023;147:759-767.
     PubMed     Abstract available
     
     
     December 2022
165. SHELBAYA K, Claggett B, Dorbala P, Skali H, et al
     Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
     Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061396.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.